FDA Approves First Biomarker-Driven Drug for HCC FDA Approves First Biomarker-Driven Drug for HCC

Ramucirumab is for the treatment of hepatocellular carcinoma in patients with an alpha-fetoprotein level of 400 ng/mL or higher.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news